Literature DB >> 1418307

Rejection associated with early appearance of donor-reactive antibodies after kidney transplantation treated with plasmapheresis and administration of 15-deoxyspergualin. A report of two cases.

G Gannedahl1, S Ohlman, U Persson, S Gudmundsson, E Larsson, G Tydén, T H Tötterman, B Wikström, L Weiss, C G Groth.   

Abstract

In two kidney transplant patients, one of whom had panel-reactive antibodies (PRA) before transplantation, a pretransplant negative donor-recipient crossmatch became positive within the 1st week after transplantation. Simultaneously, good graft function deteriorated to a state of anuria. One patient graft biopsy showed a vascular rejection, whilst the other patient biopsy was unrevealing. Both patients were treated with plasmapheresis and a new immunosuppressive drug, 15-deoxyspergualin (DSG). Plasmapheresis was performed for 6 and 9 days, respectively, and DSG was given for 5 days in a dosage of 6 mg/kg body weight per day. One of the patients received methylprednisolone i.v. in addition. During treatment the cross-match became negative and has since remained that way. In both patients the graft function was restored. No adverse effects were seen from the treatment, except for a slight leukocytopenia and thrombocytopenia.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1418307     DOI: 10.1007/bf00336067

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  2 in total

Review 1.  [Alloantibodies-mediated kidney transplant rejection: a pair of continuing approaches, and with nonetheless many open questions].

Authors:  Georg Böhmig
Journal:  Wien Klin Wochenschr       Date:  2006-07       Impact factor: 1.704

2.  Deoxyspergualin, an immunosuppressant, in patients suffering from nephropathies with crescent formation: an open-label trial to evaluate safety and efficacy.

Authors:  Hirokazu Imai; Osamu Hotta; Mitsuhiro Yoshimura; Tsuneo Konta; Yoshiharu Tsubakihara; Masanobu Miyazaki; Chie Tomida; Masaki Kobayashi; Satoshi Suzuki; Hideo Shiiki; Atsushi Yamauchi; Hitoshi Yokoyama; Masato Nose
Journal:  Clin Exp Nephrol       Date:  2006-03       Impact factor: 2.801

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.